Breast cancer and hormone-replacement therapy in the Million Women Study

Lancet

Volumn 362, Issue 9382, 2003, Pages 419-427

  Banks, Emily ^a   Beral, Valerie ^a   Bull, Diana ^a   Reeves, Gillian ^a   Austoker, Joan ^a   English, Ruth ^a   Patnick, Julietta ^a   Peto, Richard ^a   Vessey, Martin ^a   Wallis, Matthew ^a   Abbott, Simon ^a   Bailey, Emma ^a   Baker, Krys ^a   Balkwill, Angela ^a   Barnes, Isobel ^a   Black, Judith ^a   Brown, Anna ^a   Cameron, Becky ^a   Canfell, Karen ^a   Cliff, Andrea ^a   Crossley, Barbara ^a   Couto, Elisabeth ^a   Davies, Stephen ^a   Ewart, Dave ^a   Ewart, Sarah ^a   Ford, Debbie ^a   Gerrard, Laura ^a   Goodill, Adrian ^a   Green, Jane ^a   Gray, Winifred ^a   Hilton, Elizabeth ^a   Hogg, Ann ^a   Hooley, Joy ^a   Hurst, Anna ^a   Wan Kan, Sau ^a   Keene, Carol ^a   Langston, Nicky ^a   Roddam, Andrew ^a   Saunders, Phil ^a   Sherman, Emma ^a   Simmonds, Moya ^a   Spencer, Elizabeth ^a   Strange, Helena ^a   Timadjer, Alison ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; PROGESTERONE; TIBOLONE;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGISTRY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL SIGNIFICANCE; UNITED KINGDOM;

EID: 0042018741     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)14065-2     Document Type: Article

References (24)

1. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet. 350:1997;1047-1059.
2. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 288:2002;321-333.
3. Chlebowski R.T., Hendrix S.L., Langer R.D., et al. for the WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomised trial. JAMA. 289:2003;3243-3253.
4. Beral V., Banks E., Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet. 360:2002;942-944.
5. Beral V., Banks E., Reeves G., Appleby P. Use of HRT and the subsequent risk of cancer. J Epidemiol Biostat. 4:1999;191-215.
6. Berquist L., Adami H.-O., Persson I., Hoover R., Schairer C. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med. 321:1989;293-297.
7. Magnusson C., Baron J.A., Correia N., Bergstrom R., Adami H.-O., Persson I. Breast cancer risk following long-term oestrogen and oestrogen-progestin-replacement therapy. Int J Cancer. 81:1999;339-344.
8. Schairer C., Lubin J., Troisi R., Sturgeon S., Brinton L., Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA. 283:2000;485-491.
9. Ross R.K., Paganini-Hill A., Wan P.C., Pike M.C. Effect of Hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst. 92:2000;328-332.
10. Li C.I., Malone K.E., Porter P.L., Weiss N.S., et al. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA. 289:2003;3254-3263.
11. The Million Women Study: design and characteristics of the study population. Breast Cancer Res. 1:1999;73-80.
12. Banks E., Beral V., Cameron R., et al. Comparison of various characteristics of women who do and do not attend for breast cancer screening. Breast Cancer Res. 4:2001;R1.1-R1.6.
13. Patterns of use of hormone replacement therapy in one million women in Britain, 1996-2000. Br J Obst Gynaecol. 109:1996;1319-1330.
14. Banks E., Beral V., Cameron R., et al. Agreement between general practice prescription data and self-reported use of hormone replacement therapy and treatment for various illnesses. J Epidemiol Biostat. 6:2001;357-363.
15. British national formulary. 1999;BMJ Books, London.
16. International Statistical Classification of Diseases and Related Health Problems 10th revision. Geneva: World Health Organization, 1992.
17. Easton D.F., Peto J., Babiker A.G.A.G. Floating absolute risk: an alternative to relative risk in survival and case-control analysis avoiding an arbitrary reference group. Stat Med. 10:1991;1025-1035.
18. Parkin D.M., Whelan S.L., Ferlay J., Teppo L., Thomas D.B. Cancer incidence in five continents. VIII:2002;International Agency for Research on Cancer Scientific Publications, Lyon.
19. Key health statistics from general practice 1998: series MB6 (no 2). London: Office for National Statistics, 2000.
20. Cancer Research UK. Breast Cancer Factsheet, June 2003. http://www.cancerresearchuk.org/aboutcancer/statistics/statsmisc/pdfs/ factsheet_breast_jun2003.pdf (accessed July 10, 2003).
21. Pike M.C., Peters R.K., Cozen W., et al. Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst. 89:1997;1110-1116.
22. Weiderpass E., Adami H.-O., Baron J.A., et al. Risk of endometrial cancer following estrogen replacement with and without progestagins. J Natl Cancer Inst. 91:1999;1131-1137.
23. Newcomb P.A., Trentham-Deitz A. Patterns of postmenopausal progestagen use with estrogen in relation to endometrial cancer (United States). Cancer Causes Control. 14:2003;195-201.
24. Banks E. Hormone replacement therapy and the sensitivity and specificity of breast cancer screening: a review. J Med Screen. 8:2001;29-34.